Cargando…
Negative Relationship between Post-Treatment Stromal Tumor-Infiltrating Lymphocyte (TIL) and Survival in Triple-Negative Breast Cancer Patients Treated with Dose-Dense Dose-Intense NeoAdjuvant Chemotherapy
SIMPLE SUMMARY: Triple-negative breast cancer (TNBC) continues to have a poor prognosis unless a complete pathological response is achieved after neoadjuvant chemotherapy (NAC). The identification of prognostic factors would help to improve care. The evaluation of tumor-infiltrating lymphocyte (TIL)...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909288/ https://www.ncbi.nlm.nih.gov/pubmed/35267639 http://dx.doi.org/10.3390/cancers14051331 |
_version_ | 1784666104210128896 |
---|---|
author | Giacchetti, Sylvie Faucheux, Lilith Gardair, Charlotte Cuvier, Caroline de Roquancourt, Anne Campedel, Luca Groheux, David de Bazelaire, Cedric Lehmann-Che, Jacqueline Miquel, Catherine Cahen Doidy, Laurence Amellou, Malika Madelaine, Isabelle Reyal, Fabien Someil, Laetitia Hocini, Hamid Hennequin, Christophe Teixeira, Luis Espié, Marc Chevret, Sylvie Soumelis, Vassili Hamy, Anne-Sophie |
author_facet | Giacchetti, Sylvie Faucheux, Lilith Gardair, Charlotte Cuvier, Caroline de Roquancourt, Anne Campedel, Luca Groheux, David de Bazelaire, Cedric Lehmann-Che, Jacqueline Miquel, Catherine Cahen Doidy, Laurence Amellou, Malika Madelaine, Isabelle Reyal, Fabien Someil, Laetitia Hocini, Hamid Hennequin, Christophe Teixeira, Luis Espié, Marc Chevret, Sylvie Soumelis, Vassili Hamy, Anne-Sophie |
author_sort | Giacchetti, Sylvie |
collection | PubMed |
description | SIMPLE SUMMARY: Triple-negative breast cancer (TNBC) continues to have a poor prognosis unless a complete pathological response is achieved after neoadjuvant chemotherapy (NAC). The identification of prognostic factors would help to improve care. The evaluation of tumor-infiltrating lymphocyte (TIL) levels is recommended in patients with breast cancer, but little is known about changes in these levels with treatment. We studied a series of 117 TNBCs treated by dose-dense dose-intense (dd-di) NAC, to identify factors associated with pre- and post-NAC stromal TIL levels, and oncological outcomes. Our findings highlight the complexity of TIL level interpretation and the importance of taking NAC regimen into account when interpreting results. We show that patients with persistently high TIL levels after NAC are at higher risk of relapse and death. ABSTRACT: Background: Patients with triple-negative breast cancers (TNBC) have a poor prognosis unless a pathological complete response (pCR) is achieved after neoadjuvant chemotherapy (NAC). Few studies have analyzed changes in TIL levels following dose-dense dose-intense (dd-di) NAC. Patients and methods: From 2009 to 2018, 117 patients with TNBC received dd-di NAC at our institution. We aimed to identify factors associated with pre- and post-NAC TIL levels, and oncological outcomes relapse-free survival (RFS), and overall survival (OS). Results: Median pre-NAC and post-NAC TIL levels were 15% and 3%, respectively. Change in TIL levels with treatment was significantly correlated with metabolic response (SUV) and pCR. High post-NAC TIL levels were associated with a weak metabolic response after two cycles of NAC, with the presence of residual disease and nodal involvement at NAC completion. In multivariate analyses, high post-NAC TIL levels independently predicted poor RFS and poor OS (HR = 1.4 per 10% increment, 95%CI (1.1; 1.9) p = 0.014 and HR = 1.8 per 10% increment 95%CI (1.3–2.3), p < 0.0001, respectively). Conclusion: Our results suggest that TNBC patients with TIL enrichment after NAC are at higher risk of relapse. These patients are potential candidates for adjuvant treatment, such as immunotherapy, in clinical trials. |
format | Online Article Text |
id | pubmed-8909288 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89092882022-03-11 Negative Relationship between Post-Treatment Stromal Tumor-Infiltrating Lymphocyte (TIL) and Survival in Triple-Negative Breast Cancer Patients Treated with Dose-Dense Dose-Intense NeoAdjuvant Chemotherapy Giacchetti, Sylvie Faucheux, Lilith Gardair, Charlotte Cuvier, Caroline de Roquancourt, Anne Campedel, Luca Groheux, David de Bazelaire, Cedric Lehmann-Che, Jacqueline Miquel, Catherine Cahen Doidy, Laurence Amellou, Malika Madelaine, Isabelle Reyal, Fabien Someil, Laetitia Hocini, Hamid Hennequin, Christophe Teixeira, Luis Espié, Marc Chevret, Sylvie Soumelis, Vassili Hamy, Anne-Sophie Cancers (Basel) Article SIMPLE SUMMARY: Triple-negative breast cancer (TNBC) continues to have a poor prognosis unless a complete pathological response is achieved after neoadjuvant chemotherapy (NAC). The identification of prognostic factors would help to improve care. The evaluation of tumor-infiltrating lymphocyte (TIL) levels is recommended in patients with breast cancer, but little is known about changes in these levels with treatment. We studied a series of 117 TNBCs treated by dose-dense dose-intense (dd-di) NAC, to identify factors associated with pre- and post-NAC stromal TIL levels, and oncological outcomes. Our findings highlight the complexity of TIL level interpretation and the importance of taking NAC regimen into account when interpreting results. We show that patients with persistently high TIL levels after NAC are at higher risk of relapse and death. ABSTRACT: Background: Patients with triple-negative breast cancers (TNBC) have a poor prognosis unless a pathological complete response (pCR) is achieved after neoadjuvant chemotherapy (NAC). Few studies have analyzed changes in TIL levels following dose-dense dose-intense (dd-di) NAC. Patients and methods: From 2009 to 2018, 117 patients with TNBC received dd-di NAC at our institution. We aimed to identify factors associated with pre- and post-NAC TIL levels, and oncological outcomes relapse-free survival (RFS), and overall survival (OS). Results: Median pre-NAC and post-NAC TIL levels were 15% and 3%, respectively. Change in TIL levels with treatment was significantly correlated with metabolic response (SUV) and pCR. High post-NAC TIL levels were associated with a weak metabolic response after two cycles of NAC, with the presence of residual disease and nodal involvement at NAC completion. In multivariate analyses, high post-NAC TIL levels independently predicted poor RFS and poor OS (HR = 1.4 per 10% increment, 95%CI (1.1; 1.9) p = 0.014 and HR = 1.8 per 10% increment 95%CI (1.3–2.3), p < 0.0001, respectively). Conclusion: Our results suggest that TNBC patients with TIL enrichment after NAC are at higher risk of relapse. These patients are potential candidates for adjuvant treatment, such as immunotherapy, in clinical trials. MDPI 2022-03-04 /pmc/articles/PMC8909288/ /pubmed/35267639 http://dx.doi.org/10.3390/cancers14051331 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Giacchetti, Sylvie Faucheux, Lilith Gardair, Charlotte Cuvier, Caroline de Roquancourt, Anne Campedel, Luca Groheux, David de Bazelaire, Cedric Lehmann-Che, Jacqueline Miquel, Catherine Cahen Doidy, Laurence Amellou, Malika Madelaine, Isabelle Reyal, Fabien Someil, Laetitia Hocini, Hamid Hennequin, Christophe Teixeira, Luis Espié, Marc Chevret, Sylvie Soumelis, Vassili Hamy, Anne-Sophie Negative Relationship between Post-Treatment Stromal Tumor-Infiltrating Lymphocyte (TIL) and Survival in Triple-Negative Breast Cancer Patients Treated with Dose-Dense Dose-Intense NeoAdjuvant Chemotherapy |
title | Negative Relationship between Post-Treatment Stromal Tumor-Infiltrating Lymphocyte (TIL) and Survival in Triple-Negative Breast Cancer Patients Treated with Dose-Dense Dose-Intense NeoAdjuvant Chemotherapy |
title_full | Negative Relationship between Post-Treatment Stromal Tumor-Infiltrating Lymphocyte (TIL) and Survival in Triple-Negative Breast Cancer Patients Treated with Dose-Dense Dose-Intense NeoAdjuvant Chemotherapy |
title_fullStr | Negative Relationship between Post-Treatment Stromal Tumor-Infiltrating Lymphocyte (TIL) and Survival in Triple-Negative Breast Cancer Patients Treated with Dose-Dense Dose-Intense NeoAdjuvant Chemotherapy |
title_full_unstemmed | Negative Relationship between Post-Treatment Stromal Tumor-Infiltrating Lymphocyte (TIL) and Survival in Triple-Negative Breast Cancer Patients Treated with Dose-Dense Dose-Intense NeoAdjuvant Chemotherapy |
title_short | Negative Relationship between Post-Treatment Stromal Tumor-Infiltrating Lymphocyte (TIL) and Survival in Triple-Negative Breast Cancer Patients Treated with Dose-Dense Dose-Intense NeoAdjuvant Chemotherapy |
title_sort | negative relationship between post-treatment stromal tumor-infiltrating lymphocyte (til) and survival in triple-negative breast cancer patients treated with dose-dense dose-intense neoadjuvant chemotherapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909288/ https://www.ncbi.nlm.nih.gov/pubmed/35267639 http://dx.doi.org/10.3390/cancers14051331 |
work_keys_str_mv | AT giacchettisylvie negativerelationshipbetweenposttreatmentstromaltumorinfiltratinglymphocytetilandsurvivalintriplenegativebreastcancerpatientstreatedwithdosedensedoseintenseneoadjuvantchemotherapy AT faucheuxlilith negativerelationshipbetweenposttreatmentstromaltumorinfiltratinglymphocytetilandsurvivalintriplenegativebreastcancerpatientstreatedwithdosedensedoseintenseneoadjuvantchemotherapy AT gardaircharlotte negativerelationshipbetweenposttreatmentstromaltumorinfiltratinglymphocytetilandsurvivalintriplenegativebreastcancerpatientstreatedwithdosedensedoseintenseneoadjuvantchemotherapy AT cuviercaroline negativerelationshipbetweenposttreatmentstromaltumorinfiltratinglymphocytetilandsurvivalintriplenegativebreastcancerpatientstreatedwithdosedensedoseintenseneoadjuvantchemotherapy AT deroquancourtanne negativerelationshipbetweenposttreatmentstromaltumorinfiltratinglymphocytetilandsurvivalintriplenegativebreastcancerpatientstreatedwithdosedensedoseintenseneoadjuvantchemotherapy AT campedelluca negativerelationshipbetweenposttreatmentstromaltumorinfiltratinglymphocytetilandsurvivalintriplenegativebreastcancerpatientstreatedwithdosedensedoseintenseneoadjuvantchemotherapy AT groheuxdavid negativerelationshipbetweenposttreatmentstromaltumorinfiltratinglymphocytetilandsurvivalintriplenegativebreastcancerpatientstreatedwithdosedensedoseintenseneoadjuvantchemotherapy AT debazelairecedric negativerelationshipbetweenposttreatmentstromaltumorinfiltratinglymphocytetilandsurvivalintriplenegativebreastcancerpatientstreatedwithdosedensedoseintenseneoadjuvantchemotherapy AT lehmannchejacqueline negativerelationshipbetweenposttreatmentstromaltumorinfiltratinglymphocytetilandsurvivalintriplenegativebreastcancerpatientstreatedwithdosedensedoseintenseneoadjuvantchemotherapy AT miquelcatherine negativerelationshipbetweenposttreatmentstromaltumorinfiltratinglymphocytetilandsurvivalintriplenegativebreastcancerpatientstreatedwithdosedensedoseintenseneoadjuvantchemotherapy AT cahendoidylaurence negativerelationshipbetweenposttreatmentstromaltumorinfiltratinglymphocytetilandsurvivalintriplenegativebreastcancerpatientstreatedwithdosedensedoseintenseneoadjuvantchemotherapy AT amelloumalika negativerelationshipbetweenposttreatmentstromaltumorinfiltratinglymphocytetilandsurvivalintriplenegativebreastcancerpatientstreatedwithdosedensedoseintenseneoadjuvantchemotherapy AT madelaineisabelle negativerelationshipbetweenposttreatmentstromaltumorinfiltratinglymphocytetilandsurvivalintriplenegativebreastcancerpatientstreatedwithdosedensedoseintenseneoadjuvantchemotherapy AT reyalfabien negativerelationshipbetweenposttreatmentstromaltumorinfiltratinglymphocytetilandsurvivalintriplenegativebreastcancerpatientstreatedwithdosedensedoseintenseneoadjuvantchemotherapy AT someillaetitia negativerelationshipbetweenposttreatmentstromaltumorinfiltratinglymphocytetilandsurvivalintriplenegativebreastcancerpatientstreatedwithdosedensedoseintenseneoadjuvantchemotherapy AT hocinihamid negativerelationshipbetweenposttreatmentstromaltumorinfiltratinglymphocytetilandsurvivalintriplenegativebreastcancerpatientstreatedwithdosedensedoseintenseneoadjuvantchemotherapy AT hennequinchristophe negativerelationshipbetweenposttreatmentstromaltumorinfiltratinglymphocytetilandsurvivalintriplenegativebreastcancerpatientstreatedwithdosedensedoseintenseneoadjuvantchemotherapy AT teixeiraluis negativerelationshipbetweenposttreatmentstromaltumorinfiltratinglymphocytetilandsurvivalintriplenegativebreastcancerpatientstreatedwithdosedensedoseintenseneoadjuvantchemotherapy AT espiemarc negativerelationshipbetweenposttreatmentstromaltumorinfiltratinglymphocytetilandsurvivalintriplenegativebreastcancerpatientstreatedwithdosedensedoseintenseneoadjuvantchemotherapy AT chevretsylvie negativerelationshipbetweenposttreatmentstromaltumorinfiltratinglymphocytetilandsurvivalintriplenegativebreastcancerpatientstreatedwithdosedensedoseintenseneoadjuvantchemotherapy AT soumelisvassili negativerelationshipbetweenposttreatmentstromaltumorinfiltratinglymphocytetilandsurvivalintriplenegativebreastcancerpatientstreatedwithdosedensedoseintenseneoadjuvantchemotherapy AT hamyannesophie negativerelationshipbetweenposttreatmentstromaltumorinfiltratinglymphocytetilandsurvivalintriplenegativebreastcancerpatientstreatedwithdosedensedoseintenseneoadjuvantchemotherapy |